Real-world data demonstrates that a subset of node-negative (N0) breast cancer patients with high-risk features has a recurrence and mortality rate nearly identical to that of node-positive (N1) patients. This finding justifies intensifying adjuvant therapy with agents like CDK4/6 inhibitors for this seemingly lower-risk group, as was done in the NATALEE trial.

Expert clinicians select genomic assays with nuance. For a patient where a low-risk result is desired to avoid chemotherapy, Oncotype DX may be chosen as it tends to yield more low-risk scores. Conversely, MammaPrint may be used for a chemo-hesitant patient, as it is more likely to return a high-risk result.

Large-scale SEER database analysis shows that patients with T1A and T1B node-negative triple-negative breast cancer had similar outcomes whether they received chemotherapy or were just observed. This challenges the default use of chemotherapy for all patients with very early-stage TNBC.

Contrary to the belief that HR+ breast cancer primarily carries a late recurrence risk, data shows high-risk, node-positive patients can be extremely aggressive early on. With recurrence rates up to 29.1% within five years, this subgroup can perform as poorly, or even worse, than triple-negative breast cancer, highlighting the need for intensive adjuvant therapy.

An increasing proportion of metastatic breast cancer is diagnosed de novo, not as a recurrence. This seemingly negative trend is actually a positive sign that adjuvant therapies are successfully curing more patients with early-stage disease.

Despite low individual recurrence rates, the vast number of women diagnosed with early-stage breast cancer means they account for most deaths. The annual proportion of deaths from stage 2 disease rose from 26% to 40%, while stage 1 accounts for another 23%. This highlights the need for better monitoring, like ctDNA, in this population.

A subset of breast cancers (10-15%) are "non-shedders," meaning they don't release detectable ctDNA. Patients with these tumors have excellent outcomes regardless of chemotherapy, suggesting that surgery alone might be a sufficient and less toxic treatment for this specific group.

The Oncotype DX score effectively predicts the overall risk of recurrence for early-stage breast cancer, but it provides no information about the biological behavior of the tumor if it does recur. A tumor with a low-risk score can unfortunately return as a highly aggressive, dangerous disease, highlighting a critical limitation of the prognostic test.

The financial impact of cancer is not uniform over time. The most significant income reductions, between 15-20%, occur in the year of diagnosis and the two subsequent years. This period aligns with active treatment and time away from work, highlighting a critical window for targeted financial interventions and support.